‘The Market for Parkinson’s Disease Drugs Will Reach $3754m in 2015′ Says visiongain Report

LONDON, September 27, 2011 -

www.visiongain.com/Report/689/Parkinson%27s-Disease-World-Drug-Market-2011-2021

A new report by visiongain, a London-based business information provider, predicts that the market for Parkinson’s disease drugs will reach $3754m in 2015.  This decade, new products, including adenosine receptor antagonists, will benefit the Parkinson’s treatment market and stimulate growth of overall revenue.

The market for Parkinson’s disease drugs generated $3351m in 2010, according to Parkinson’s Disease: World Drug Market 2011-2021, published in September 2011. The Parkinson’s treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson’s drugs in progress.

Parkinson’s disease is a prominent neurodegenerative disorder. Though it is primarily a movement disorder, with symptoms including tremor and bradykinesia, it often causes cognitive effects including dementia and psychosis. Because Parkinson’s affects mostly the elderly, the ageing of the world population will result in its prevalence increasing, giving opportunities to the pharmaceutical industry.

The disease remains chronic and incurable, but since the 1960s treatments have relieved some of the symptoms. Many treatments are approaching - or have reached - commercial maturity, but a strong R&D pipeline stands ready to replace them. Visiongain’s report discusses leading drug candidates, including new adenosine receptor antagonists. That study covers Boehringer Ingelheim, Novartis, GSK, Teva and many other companies, predicting revenues and developmental trends to 2021.

Visiongain’s healthcare industry analyst, says: “Parkinson’s remains the most treatable of the neurodegenerative diseases, but the industry needs a new approach to supplement dopaminergic therapies. Longer term, gene therapies, biomarkers and stem cells point the way to disease modification and an eventual cure. In coming years, adenosine receptor antagonists will boost the Parkinson’s treatment armoury. Those drugs offer a way to bypass the dopamine system and restore damaged communicational links in the brain. Kyowa Hakko Kirin has the leading product candidate.”

Research and analyses from visiongain’s report indicate that scientific and industrial studies of Parkinson’s disease will yield important developments in the next ten years. While dopaminergic treatments will remain important, drugs with other mechanisms of action will enter the market and improve treatment of patients.      

Visiongain predicts that the Parkinson’s treatment market will grow steadily to 2021, with some existing drugs being superseded by newer treatments. This new report adds to visiongain’s wide range of analytical reports for healthcare and other industries.

To see sample pages of the report please click on:

www.visiongain.com/Report/689/Parkinson%27s-Disease-World-Drug-Market-2011-2021

Table of content:
1. Executive Summary
1.1 Parkinson’s Disease: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods

2. Parkinson’s Disease in 2011: A Scientific and Clinical Overview
2.1 Parkinson’s is Characterised by Dopamine Depletion
2.2 Motor Symptoms of Parkinson’s Disease
2.2.1 Tremor
2.2.2 Rigidity
2.2.3 Bradykinesia
2.2.4 Postural Instability
2.2.5 Other Motor Symptoms
2.3 Cognitive, Behavioural and Other Symptoms
2.3.1 Cognitive Deficits
2.3.2 Behavioural and Mood Difficulties
2.3.3 Other Symptoms
2.4 Subtypes and Possible Origin of the Disease
2.5 Timeline of Parkinson’s Disease Treatment

3. The Global Market for Parkinson’s Disease Drugs 2011-2021
3.1 The Parkinson’s Disease Market: Overview 2011-2021
3.2 The Parkinson’s Disease Market: Breakdown 2011-2021
3.3 Dopaminergic Agents: Still Key to the Market
3.3.1 Dopaminergic Agents: Market Forecast 2011-2021
3.4 Dopamine Agonists: The Foremost Commercial Class of Parkinson’s Drugs
3.4.1 Dopamine Agonists: Market Forecast 2011-2021
3.5 COMT Inhibitors: The Best-Selling Class in the Parkinson’s Drug Market
3.5.1 COMT Inhibitors: Market Forecast 2011-2021
3.6 MAO Inhibitors: The Fastest-Growing Market Sector
3.6.1 MAO Inhibitors: Market Forecast 2011-2021
3.7 Other Classes of Parkinson’s Disease Treatment
3.7.1 Other Classes of Parkinson’s Disease Treatment: Market Forecast 2011-2021

4. Leading Products in the Parkinson’s Disease Treatment Market
4.1 Four Drugs Lead the Market
4.2 Stalevo and Comtess (Orion/Novartis)
4.2.1 Stalevo and Comtess: Sales Forecast 2011-2021
4.3 Sifrol (Boehringer Ingelheim)
4.3.1 Sifrol: Sales Forecast 2011-2021
4.4 Azilect (Teva Pharmaceuticals)
4.4.1 Azilect: Sales Forecast 2011-2021
4.5 Requip (GlaxoSmithKline)
4.5.1 Requip: Sales Forecast 2011-2021
4.6 Other Products
4.6.1 Other Products: Market Forecast 2011-2021

5. Leading National Markets for Parkinson’s Treatments 2011-2021
5.1 The US is the Largest Market
5.2 The US: Market Forecast 2011-2021
5.3 The EU5: Market Forecasts 2011-2021
5.4 Japan: Market Forecast 2011-2021
5.5 China: Market Forecast 2011-2021
5.6 India: Market Forecast 2011-2021
5.7 Rest of the World: Market Forecast 2011-2021

6. Parkinson’s Disease Treatments: R&D Pipeline Analysis 2011
6.1 There are More than 300 Late-Stage Trials of Parkinson’s Drugs in Progress in 2011
6.2 KW-6002 (Kyowa Hakko Kirin) and Other Adenosine Receptor Antagonists
6.3 Safinamide (Merck Serono): Both Dopaminergic and Non-dopaminergic Effects?
6.4 Fipamezole (Santhera Pharmaceuticals)
6.5 Coenzyme Q10 (National Institute of Neurological Disorders and Stroke [NINDS], and Others)
6.6 Potential Gene Therapies
6.7 CERE-120 (Ceregene): Lead Gene-Therapy Product
6.8 Neurologix: Another Gene Therapy Candidate
6.9 Possible Disease-Modifying Treatments

7. Top Companies in the Parkinson’s Disease Treatments Market 2011
7.1 Boehringer Ingelheim
7.2 Novartis
7.3 Orion
7.4 Teva Pharmaceutical Industries
7.5 GlaxoSmithKline
7.6 Impax Laboratories
7.7 Kyowa Hakko Kirin
7.8 Merck Serono
7.9 Newron
7.10 Ceregene
7.11 Neurologix
7.12 Santhera
7.13 Biotie
7.14 Merck & Co
7.15 Xenoport

8. Parkinson’s Treatment Market: Qualitative Analysis
8.1 Strengths: Parkinson’s Disease is a Widely Prevalent and Treatable Disease
8.2 Weaknesses: Products on the Market Have Limitations and Can Be Superseded
8.3 Opportunities: Neurodegenerative Disorder Treatments Are a Fertile R&D Area
8.4 Threats: New Parkinson’s Treatments May Be Subject to Political, Commercial and Social Pressures

9. Research Interviews from Our Survey
9.1 Interview with Dr Kieran Breen
9.1.1 On Current Treatment Options for Parkinson’s Disease
9.1.2 On Prospective New Drugs
9.1.3 On Cell Death and Neuroprotection
9.1.4 On Braak’s Hypothesis and Parkinson’s Disease Progression
9.1.5 On Disease Heterogeneity and Potential Biomarkers
9.1.6 On Growth Factors, Gene Therapies and Stem Cells
9.1.7 On Brain-Banking and Animal Models
9.2 Interview with Professor Rammohan Rao
9.2.1 On the Role of the Endoplasmic Reticulum in Cell Death
9.2.2 On Therapeutic Applications of That Research
9.2.3 On Challenges in the Parkinson’s Disease Field in 2011

10. Conclusions from Our Study
10.1 Parkinson’s Disease Treatment Market to 2021
10.2 A Promising But Unproven Pipeline
10.3 Other Factors Will Benefit the Parkinson’s Disease Treatment Market

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

To request an exec summary please contact Sara Peerun on:
Email: sara.peerun@visiongainglobal.com
Tel: +44 0 20 7336 6100
Web: www.visiongain.com

.